eScholarship
metadata only
CC BY
Revealing imatinib-kinase specificity via analyzing changes in protein dynamics and computing molecular binding affinity
Drug promiscuity is a double-edged sword where a small molecule acts on multiple biological targets to induce toxicological or therapeutic benefits. It is possible to exploit promiscuity to expand treatment options without the prohibitive costs of designing a new drug. Imatinib is a representative c
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Immune Monitoring in Metastatic Melanoma#905658
- A Phase II Study of Apatinib in STS Patients#833709
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia#892740
- Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma#1044423
- MolClaw: An Autonomous Agent with Hierarchical Skills for Drug Molecule Evaluation, Screening, and Optimization#157830
Record · ID 1250102
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive